Mechanistically, YY1 activates oncogenic pathways, such as c-Myc and human epidermal growth factor receptor 2 (HER2), while suppressing those of tumor suppressors, including p53 as well as phosphatase and tensin homolog (PTEN), thereby promoting the cancer process. Here, ERBB2 is linked to neoplasm.